Vaxart News

B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating

MT NewswiresJun 14 19:42

Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements

TipRanksMar 20 19:31

Vaxart Spikes as B. Riley Upgrades at Long Last After BARDA Funding

Seeking AlphaFeb 1 03:13

B. Riley Securities Upgrades Vaxart to Buy, Announces $2 Price Target

BenzingaJan 31 22:48

Vaxart Analyst Ratings

BenzingaJan 31 22:46

Analysts' Top Healthcare Picks: Vaxart (VXRT), Palisade Bio (PALI)

TipRanksJan 31 20:40

Analyst Holds Vaxart Stock Rating Amid Positive Clinical Trials and Robust Vaccine Development Prospects

TipRanksNov 7, 2023 23:15

Vaxart (VXRT) Receives a Buy From Cantor Fitzgerald

TipRanksSep 11, 2023 02:25

B.Riley Financial Remains a Hold on Vaxart (VXRT)

TipRanksSep 8, 2023 02:45

Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

BenzingaSep 7, 2023 21:21

Vaxart Analyst Ratings

BenzingaSep 7, 2023 21:21

Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

BenzingaAug 7, 2023 21:07

Vaxart Analyst Ratings

BenzingaAug 7, 2023 21:02

B.Riley Financial Remains a Hold on Vaxart (VXRT)

TipRanksJul 7, 2023 23:45

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vaxart (VXRT) and Tarsus Pharmaceuticals (TARS)

TipRanksMay 9, 2023 00:20

Jefferies Keeps Their Buy Rating on Vaxart (VXRT)

TipRanksMar 29, 2023 20:17

B.Riley Financial Sticks to Its Hold Rating for Vaxart (VXRT)

TipRanksMar 17, 2023 00:51

B.Riley Financial Keeps Their Hold Rating on Vaxart (VXRT)

TipRanksFeb 28, 2023 06:45

Vaxart Analyst Ratings

Benzinga Analyst RatingsDec 19, 2022 21:32

B. Riley Securities Maintains Neutral on Vaxart, Lowers Price Target to $1.5

Benzinga Real-time NewsDec 19, 2022 21:31